my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
09-18-2007: Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million.
As part of the transaction, which was announced in March 2007, Novartis has transferred manufacturing responsibility to Bayer Schering for interferon beta-1b and received the one-time payment for the transfer of production equipment, inventory and the leasing of buildings at a site in Emeryville, California.
Novartis will continue to receive royalties until October 2008 from Bayer Schering for its global sales of Betaseron, which is an injectable treatment of relapsing forms of multiple sclerosis - a disease estimated to affect more than 2.5 million patients worldwide and one of the leading causes of neurological disability in young adults.
Novartis will be supported by Bayer Schering in the regulatory filing process of a Novartis-branded version of Betaseron, and this product is expected to be introduced in 2009. The launch of this brand is expected to give Novartis an increasing presence in treating patients with relapsing forms of multiple sclerosis ahead of its anticipated submission of a once-daily oral therapy FTY720 (fingolimod), which is currently in Phase III trials. Novartis expects to submit FTY720 for US and EU approvals in 2009.
Betaseron is currently marketed by Bayer Schering, which was created after Bayer acquired Schering in 2006. In 1993, Schering signed an agreement with Chiron Corporation (Chiron) covering the regulatory filing, development and supply of Betaseron. Novartis acquired Chiron in 2006. Novartis assumed the rights to this product through the purchase of Chiron.
Watchlist
This is where you can add this news to your personal favourites
Orion sues Sun Pharmaceuticals in the U.S. to enforce a patent for Stalevo
Orion Corporation has filed a patent infringement lawsuit in the United States to enforce its formulation patent, U.S. Patent No. 6,500,867, against Sun Pharmaceutical Industries Inc. and Sun Pharmaceutical Industries Limited, who seek to market generic versions of Stalevo® tablets (25/100/ ... more
Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing
Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was anno ... more
Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis
Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron® at the Emeryville site, retain full control of all manufacturing and process technolo ... more
Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing
Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was anno ... more
Chiron Delivers FLUVIRIN(R) Influenza Virus Vaccine to U.S. Customer
Chiron Corporation announced that it has initiated the first delivery and release of FLUVIRIN(R) influenza virus vaccine to customers in the United States for the 2005-2006 influenza season. The company expects to continue to deliver shipments of FLUVIRIN vaccine throughout October and Nove ... more
Chiron Responds to Novartis Offer
Chiron Corporation issued the following statement from Chiron's independent board directors in response to the offer from Novartis AG on September 1, 2005, to acquire the approximately 58% of Chiron shares that Novartis does not already own for $40 per Chiron share in cash: "Over the 10 ye ... more
Chiron is a 20 year old company with main office in the lovely city of Trondheim in the northern country of Norway. Our staff is comprised of 17 talented people with backgrounds in Chemistry, Biochemistry and Economics. Gruppebilde-ChironSince 1983 we have supplied reference standards of ... more
Novartis completes agreement with Bayer Schering related to Betaseron rights and manufacturing
Novartis has completed an agreement with Bayer Schering Pharma AG (Bayer Schering) related to various rights for the multiple sclerosis treatment Betaseron® (interferon beta-1b) and has received a one-time payment of approximately USD 200 million. As part of the transaction, which was anno ... more
Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis
Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron® at the Emeryville site, retain full control of all manufacturing and process technolo ... more
Bayer HealthCare announces concrete plans for the global synergy goals and job cuts
Bayer HealthCare published concrete plans regarding the previously announced synergy goals. The integration of the activities of the former Schering AG, Germany, with the Pharma division of Bayer HealthCare shall result in annual savings of EUR 700 million from 2009. Adjustments to personne ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
